Lumexa Imaging Holdings Inc

Lumexa Imaging Holdings Inc (LMRI) Stock Analysis

$10.780

0.000 (0.00%)At close

Loading chart…
High
11.000
Open
10.810
VWAP
10.80
Volume
318.53K
Mkt Cap
—
Low
10.610
Amount
3.44M
EV/EBITDA, TTM
20.75

Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.

AI analysis of Lumexa Imaging Holdings Inc (LMRI)

Buy

Lumexa Imaging Holdings, Inc. is a good buy right now due to its recent positive earnings surprise of 233.33% and a current price of $10.78, which is significantly below analyst price targets of $18 from both Truist and KeyBanc. The company has shown a recovery in net income with a positive net income of $2.74 million in Q2 2026, indicating a turnaround in profitability. However, the main risk is its high debt to equity ratio of 144.68%, which could impact financial stability if not managed carefully.

Valuation Metrics

The current forward P/E ratio for Lumexa Imaging Holdings Inc (LMRI) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
35.60
Current EV/EBITDA
20.75
Overvalued
60.04
Undervalued
11.17

Forward P/S

Fair
5Y Average P/S
0.90
Current P/S
0.92
Overvalued
1.20
Undervalued
0.60

Whales holding LMRI

S

Seven Grand Managers LLC

+ HoldingLMRI

-1.91%

3M Return

Events Timeline

2026-08-12 (ET)

17:00:00

Company Adjusts FY26 Revenue Outlook to $1.05B-$1.1B

17:00:00

Lumexa Imaging Reports Q2 Revenue of $264.16M

2026-06-02 (ET)

07:30:00

Lumexa Imaging Forms Strategic Joint Venture with Hospital for Special Surgery

2026-04-20 (ET)

07:10:00

Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

2026-03-26 (ET)

09:40:00

Lumexa Imaging Holdings Inc Trading Halted Due to Volatility

News

LMRI FAQ — answered by Alphio AI

Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems. It operates in the Healthcare sector.

Lumexa Imaging Holdings, Inc. is a good buy right now due to its recent positive earnings surprise of 233.33% and a current price of $10.78, which is significantly below analyst price targets of $18 from both Truist and KeyBanc. The company has shown a recovery in net income with a positive net income of $2.74 million in Q2 2026, indicating a turnaround in profitability. However, the main risk is its high debt to equity ratio of 144.68%, which could impact financial stability if not managed carefully.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading